1 / 5

kDa

A. B. Control. SSAT. SPDS. SPMS. siRNA. - + + - + + - + + - + +. Doxycycline. s i ODC. Control. - - + - - + - - + - - +. kDa. Doxorubicin. 58. kDa. 0 4 8 0 4 8. Doxorubicin (Hrs ):. DNp73β. 58. DNp73. 46.

karmac
Download Presentation

kDa

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. A B Control SSAT SPDS SPMS siRNA - + + - + + - + + - + + Doxycycline si ODC Control - - + - - + - - + - - + kDa Doxorubicin 58 kDa 0 4 8 0 4 8 Doxorubicin (Hrs): DNp73β 58 DNp73 46 Actin Egfp 30 odc ssat RT-PCR gapdh spds spms gapdh C D H1299 HCT116 kDa Doxorubicin (Hrs): 0 2 4 6 58 DNp73β 46 Actin Polyamine concentration (nmol/mg protein) paox gapdh Supplementary Figure 1 Bunjobpol et al.

  2. A C Vector FosB kDa CHX (Hrs) 0 1.5 3 4.5 0 1.5 3 4.5 58 DNp73β 46 FosB 30 46 Actin Vector JunB CHX (Hrs) 0 1.5 3 4.5 0 1.5 3 4.5 DNp73β JunB Actin mutant paox % DNp73 remaining B D RLU kDa kDa siRNA Vector c-Jun 58 58 Time after cycloheximide (Hrs) % DNp73 remaining CHX (Hrs) 0 2 4 6 0 2 4 6 30 DNp73β 30 46 46 c-Jun Time after cycloheximide (Hrs) Actin % DNp73 remaining Time after cycloheximide (Hrs) Supplementary Figure 2 Bunjobpol et al.

  3. si Az1 Control Vector c-Jun c-Jun Vector FosB FosB DNp73β A B c-Jun FosB Actin kDa kDa 58 az1 gapdh 17 30 46 46 30 46 DNp73β/Actin (% vector control knockdown ) μM MDL 72527 0 200 300 Az1 (p) Actin Vector c-Jun FosB c-Jun FosB Vector Az1 Control siRNA Supplementary Figure 3 Bunjobpol et al.

  4. A Thyroid Thyroid B-cell leukemia Prostate Gastric 3 2 2 2.5 2 μM MDL 72527 0 50 100 150 200 250 DNp73β 1 1 1.5 0 Normailzed paox expression units Actin 1.5 SHSY5Y DNp73β 0 0 1 -2.5 0 0 Normal (n=4) Tumour (n=14) Normal (n=74) Normal (n=9) Tumour (n=9) Normal (n=8) Normal (n=31) Tumour (n=4) Tumour (n=147) Tumour (n=13) Oncomine boxed plots B kDa 58 46 Supplementary Figure 4 Bunjobpol et al.

  5. A SHSY5Y DNp73β Vector μM Doxorubicin 0 0.25 0.5 0 0.25 0.5 - MDL 72527 + MDL 72527 +MDL +MDL Caspase3 activity SHSY5Y pcDNA SHSY5Y DNp73β C B pcDNA DNp73β kDa ΔOD400nm 58 DNp73 Propidium Iodide 46 Propidium Iodide Actin +MDL +MDL HCT116 % Ann. V+/PI+ SHSY5Y pcDNA SHSY5Y DNp73β Annexin V - FITC Annexin V - FITC D HCT116 Vector DNp73β CDDP - + - + Control Control sipaox Control sipaox HCT116 pcDNA HCT116 DNp73β sipaox Supplementary Figure 5 Bunjobpol et al.

More Related